WS #13429
Holding: newest synthesis is 98d 5h old
Novo Nordisk beat Q2 estimates with EPS $0.96 vs $0.81 est and revenue $12.209B vs $11.35B est, positive for NVO ahead of Wednesday's earnings.
Novo Nordisk Q2 Beat
Novo Nordisk beat Q2 estimates with EPS $0.96 vs $0.81 est and revenue $12.209B vs $11.35B est, positive for NVO ahead of Wednesday's earnings.